Related Experiment Video
Updated: Jul 3, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[A multi-centers clinical study of different treatment outcomes of 332 patients with multiple myeloma]
Kai Xue1, Lu-gui Qiu, Ting Liu
1Department of Hematology, Ruijin Hospital, being Affiliated to Shanghai Jiaotong University, Shanghai 200025, China. xuekaishanghai@126.com
Objective:
To describe the demographic and clinical characteristics of patients with the diagnosis of multiple myeloma (MM) and to analyse the outcome of different regimens for the treatment of MM.
Methods:
The study reviewed 332 MM cases diagnosed within the period from January 1, 2002 to December 31, 2002. These patients were tracked via their records to a total period of three years.
Results:
First-line treatment: Totally 332 patients were included, among them 325 (97.9%) patients received chemotherapy and 7 (2.1%) patients received stem cell transplantation (SCT); Second-line treatment: 197 patients were included, among them 190 (96.5%) patients received chemotherapy and 7 (3.6%) patients received SCT; Third-line treatment: 92 patients were included,among them 88 (95.7%) patients received chemotherapy and 4 (4.4%) patients received SCT. Major adverse effects were follows: severe infection 19.3%, severe anaemia 19.3%, phlebothrombosis 1.2% , thrombocytopenia 16.9%, fever associated with neutropenia 18.1%.
Conclusions:
Some curative effects can be achieved by using traditional treatment plans to treat patients suffering from MM, but new methods are expected to improve the prognosis.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Study Design: Healthy Subjects Versus Patients
Cancer Survival Analysis
Clinical Trials: Overview